Showing 741-746 of 746 for: Cochrane Systematic Reviews > Pharmacotherapeutics 
- Ziprasidone for schizophrenia and severe mental illness
Cochrane Systematic Reviews, 18-Jan-2012
Typical antipsychotic drugs are widely used as the first line treatment for people with schizophrenia. However, the atypical class of antipsychotic drugs are making important inroads into this approach. Atypical is a widely used term used to describe some
- Ziprasidone versus other atypical antipsychotics for schizophrenia
Cochrane Systematic Reviews, 7-Oct-2009
In many countries of the industrialised world second generation ('atypical') antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether, and if so how much, the effects of the various new generation
- Zotepine for schizophrenia
Cochrane Systematic Reviews, 18-Oct-2006
Zotepine is a relatively new antipsychotic often used for the treatment of people with schizophrenia. It is claimed to be particularly effective for negative symptoms.
- Zotepine versus other atypical antipsychotics for schizophrenia
Cochrane Systematic Reviews, 7-Dec-2011
In many parts of the world, particularly in industrialised countries, second generation (atypical) antipsychotic drugs have become first line treatment for people suffering from schizophrenia. The question as to whether the effects of various second gener
- Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses
Cochrane Systematic Reviews, 18-Apr-2012
Medication used for acute aggression in psychiatry must have rapid onset of effect, low frequency of administration and low levels of adverse effects. Zuclopenthixol acetate is said to have these properties.
- Zuclopenthixol decanoate for schizophrenia and other serious mental illnesses
Cochrane Systematic Reviews, 26-Jul-1999
There is a clear link between stopping antipsychotic medications and a relapse of psychotic symptoms. A series of long-acting intra-muscular preparations has been developed since the 1960s in the hope of reducing the frequency of relapse and, hence, overa
